论文部分内容阅读
目的探讨异丙托溴铵与氨溴索联合雾化吸入治疗小儿支气管肺炎的临床疗效。方法选择2013年9月—2014年10月在黔西南州人民医院进行治疗的支气管肺炎患儿288例,随机分为观察组和对照组,各144例。两组患儿均给予常规综合对症治疗,观察组则在此基础上采用异丙托溴铵与氨溴索联合雾化吸入治疗,比较两种患儿的临床症状缓解情况和疗效。结果对照组患儿总有效率为84.8%,低于观察组的95.1%,差异有统计学意义(P<0.05)。观察组患儿咳嗽、气促缓解时间以及肺部啰音消失时间短于对照组,差异有统计学意义(P<0.05)。结论异丙托溴铵与氨溴索联合雾化吸入治疗小儿支气管肺炎的疗效显著,且无任何不良反应,安全性和有效性较好。
Objective To investigate the clinical efficacy of ipratropium bromide and ambroxol combined with inhalation in the treatment of bronchial pneumonia in children. Methods 288 cases of bronchial pneumonia treated in Qianxinan People’s Hospital from September 2013 to October 2014 were randomly divided into observation group and control group, with 144 cases in each group. The two groups of children were given conventional comprehensive symptomatic treatment, the observation group was based on this combination of ipratropium bromide and ambroxol inhalation therapy, the clinical symptoms of both children to alleviate the situation and efficacy. Results The total effective rate was 84.8% in the control group, which was lower than 95.1% in the observation group, the difference was statistically significant (P <0.05). The observation group cough, shortness of breath reduction time and lung rales disappeared shorter than the control group, the difference was statistically significant (P <0.05). Conclusion The combination of ipratropium bromide and ambroxol inhalation for the treatment of children with bronchopneumonia has significant curative effect without any adverse reactions, which is safe and effective.